Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P12271
UPID:
RLBP1_HUMAN
Alternative names:
Cellular retinaldehyde-binding protein
Alternative UPACC:
P12271; B2R667
Background:
Retinaldehyde-binding protein 1, also known as Cellular retinaldehyde-binding protein, plays a pivotal role in the visual cycle. It is essential for the proper function of both rod and cone photoreceptors, facilitating the regeneration of active 11-cis-retinol and 11-cis-retinaldehyde. This process is crucial for the conversion of light into visual signals.
Therapeutic significance:
Retinaldehyde-binding protein 1 is linked to several retinal diseases, including Bothnia retinal dystrophy, Rod-cone dystrophy Newfoundland, and Retinitis punctata albescens. These conditions underscore the protein's critical role in visual health, suggesting that targeting it could lead to novel treatments for these debilitating eye diseases.